Systemic Therapy of Cholangiocarcinoma

被引：21

作者：

Plentz, Ruben R. ^{[1
]}

Malek, Nisar P. ^{[1
]}

机构：

[1] Med Univ Hosp, Dept Internal Med 1, Otfried Muller Str 10, D-72076 Tubingen, Germany

来源：

VISCERAL MEDICINE | 2016年 / 32卷 / 06期

关键词：

Chemotherapy; Cholangiocarcinoma; Survival; BILIARY-TRACT CANCER; PHASE-II TRIAL; INTRAHEPATIC CHOLANGIOCARCINOMA; GALLBLADDER CARCINOMA; 1ST-LINE TREATMENT; HER2; EXPRESSION; PLUS SORAFENIB; OPEN-LABEL; GEMCITABINE; OXALIPLATIN;

D O I：

10.1159/000453084

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Cholangiocarcinoma (CC) is the second most common primary malignant liver disease. During the last decades, various novel therapies have been introduced in the field of oncology; nevertheless, the number of treatment options for CC is still limited. Methods: In this article, current palliative chemotherapy concepts as well as new drug therapies are outlined. Results: Gemcitabine and cisplatin are the standard treatment of care for patients with inoperable CC. Second-line chemotherapy is not standardized yet and is dependent on the first-line compounds. Antibodies against VEGFR and EGFR showed mixed or negative results. New molecular systemic treatments are not established yet. Conclusion: Many clinical trials are still ongoing and new therapeutic strategies, including immunotherapies, are under active investigation. (C) 2016 S. Karger GmbH, Freiburg

引用

页码：427 / 430

页数：4

共 60 条

[1] Descriptive epidemiology of cholangiocarcinoma in Italy [J].

Alvaro, Domenico ;

Crocetti, Emanuele ;

Ferretti, Stefano ;

Bragazzi, Maria Consiglia ;

Capocaccia, Riccardo .

DIGESTIVE AND LIVER DISEASE, 2010, 42 (07) :490-495

[2] Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors [J].

Andersen, Jesper B. ;

Spee, Bart ;

Blechacz, Boris R. ;

Avital, Itzhak ;

Komuta, Mina ;

Barbour, Andrew ;

Conner, Elizabeth A. ;

Gillen, Matthew C. ;

Roskams, Tania ;

Roberts, Lewis R. ;

Factor, Valentina M. ;

Thorgeirsson, Snorri S. .

GASTROENTEROLOGY, 2012, 142 (04) :1021-U552

[3] Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study [J].

Andre, T. ;

Reyes-Vidal, J. M. ;

Fartoux, L. ;

Ross, P. ;

Leslie, M. ;

Rosmorduc, O. ;

Clemens, M. R. ;

Louvet, C. ;

Perez, N. ;

Mehmud, F. ;

Scheithauer, W. .

BRITISH JOURNAL OF CANCER, 2008, 99 (06) :862-867

[4] Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma:: a GERCOR study [J].

André, T ;

Tournigand, C ;

Rosmorduc, O ;

Provent, S ;

Maindrault-Goebel, F ;

Avenin, D ;

Selle, F ;

Paye, F ;

Hannoun, L ;

Houry, S ;

Gayet, B ;

Lotz, JP ;

de Gramont, A ;

Louvet, C .

ANNALS OF ONCOLOGY, 2004, 15 (09) :1339-1343

[5] Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer [J].

Aruga, Atsushi ;

Takeshita, Nobuhiro ;

Kotera, Yoshihito ;

Okuyama, Ryuji ;

Matsushita, Norimasa ;

Ohta, Takehiro ;

Takeda, Kazuyoshi ;

Yamamoto, Masakazu .

JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12

[6] Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers [J].

Bekaii-Saab, Tanios ;

Phelps, Mitch A. ;

Li, Xiaobai ;

Saji, Motoyasu ;

Goff, Laura ;

Kauh, John Sae Wook ;

O'Neil, Bert H. ;

Balsom, Stephanie ;

Balint, Catherine ;

Liersemann, Ryan ;

Vasko, Vasily V. ;

Bloomston, Mark ;

Marsh, William ;

Doyle, L. Austin ;

Ellison, Gilian ;

Grever, Michael ;

Ringel, Matthew D. ;

Villalona-Calero, Miguel A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2357-2363

[7] SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma [J].

Ben-Josef, Edgar ;

Guthrie, Katherine A. ;

El-Khoueiry, Anthony B. ;

Corless, Christopher L. ;

Zalupski, Mark M. ;

Lowy, Andrew M. ;

Thomas, Charles R., Jr. ;

Alberts, Steven R. ;

Dawson, Laura A. ;

Micetich, Kenneth C. ;

Thomas, Melanie B. ;

Siegel, Abby B. ;

Blanke, Charles D. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (24) :2617-U57

[8] Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial [J].

Bengala, C. ;

Bertolini, F. ;

Malavasi, N. ;

Boni, C. ;

Aitini, E. ;

Dealis, C. ;

Zironi, S. ;

Depenni, R. ;

Fontana, A. ;

Del Giovane, C. ;

Luppi, G. ;

Conte, P. .

BRITISH JOURNAL OF CANCER, 2010, 102 (01) :68-72

[9] A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer [J].

Chen, J. S. ;

Hsu, C. ;

Chiang, N. J. ;

Tsai, C. S. ;

Tsou, H. H. ;

Huang, S. F. ;

Bai, L. Y. ;

Chang, I. C. ;

Shiah, H. S. ;

Ho, C. L. ;

Yen, C. J. ;

Lee, K. D. ;

Chiu, C. F. ;

Rau, K. M. ;

Yu, M. S. ;

Yang, Y. ;

Hsieh, R. K. ;

Chang, J. Y. ;

Shan, Y. S. ;

Chao, Y. ;

Chen, L. T. .

ANNALS OF ONCOLOGY, 2015, 26 (05) :943-949

[10] Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma [J].

Cho, JY ;

Paik, YH ;

Chang, YS ;

Lee, SJ ;

Lee, DK ;

Song, SY ;

Chung, JB ;

Park, MS ;

Yu, JS ;

Yoon, DS .

CANCER, 2005, 104 (12) :2753-2758

← 1 2 3 4 5 6 →